NewKerala.com

AI to Revolutionize Drug Discovery and Healthcare, Say Pharma Experts

Experts at the India Pharma 2026 conference emphasized that artificial intelligence is pivotal for accelerating drug discovery and enabling precision medicine. The event highlighted the need to reimagine pharmaceutical processes and build strong data foundations to scale AI adoption effectively. Key discussions focused on bridging the gap between policy intent and ground execution, with calls for an industry-led R&D model and stronger industry-academia trust. The conference also noted the robust growth of India's Contract Research and Manufacturing sector, valued at $8 billion.

Key Points: AI's Pivotal Role in Accelerating Drug Discovery in India

  • AI accelerates drug discovery
  • Need for strong data foundations
  • Bridging policy and execution gap
  • Growth of India's CRDMO sector
2 min read

AI will play a pivotal role in accelerating drug discovery: Experts

Experts at India Pharma 2026 highlight AI's role in drug discovery, precision medicine, and building a smarter healthcare ecosystem.

"AI will play a pivotal role in accelerating drug discovery, enabling precision medicine and shaping a smarter, innovation-led healthcare ecosystem - Experts"

New Delhi, April 14

AI will play a pivotal role in accelerating drug discovery, enabling precision medicine and shaping a smarter, innovation-led healthcare ecosystem, according to experts.

Pharma leaders emphasised reimagining processes rather than merely digitising existing systems. They highlighted the growing importance of strong data and technology foundations to enable scalable AI adoption and stressed the immediate benefits of automation in improving clinical efficiency.

The first day of the 9th 'India Pharma 2026' witnessed four high-impact plenary sessions that brought together policymakers, industry leaders, regulators and technology experts to chart the future of India's pharmaceutical and life sciences ecosystem.

The inaugural plenary session highlighted the urgent need to bridge the gap between policy intent and on-ground execution.

Manoj Joshi, Secretary, Department of Pharmaceuticals, emphasised industry-led model for Research and Development, importance of strengthening government lab networks and attuning regulatory model to that of European systems.

Rajiv Bahl, Secretary, Department of Health Research, said though research funding has increased manifold over the last few years, the country needs a Bharat model of R&D with confidence of the market in the innovators and increased trust between industry and academia.

According to the Ministry of Chemicals and Fertilisers, industry leaders echoed the need for increased venture capital participation and co-funding mechanisms to nurture research-driven enterprises, stronger industry-academia integration and underscored the importance of integrated ecosystems to translate early-stage discoveries into global solutions.

The second plenary session focused on creating a predictable, efficient and globally aligned regulatory framework.

Dr. Rajeev Singh Raghuvanshi, Drug Controller General of India, highlighted the importance of stakeholder consultations in shaping responsive regulatory systems.

The third plenary session explored the transformative potential of artificial intelligence across the pharmaceutical value chain.

The fourth session brought focus to India's growing role in the global Contract Research, Development and Manufacturing Organisation (CRDMO) landscape.

The panel noted that India's CRDMO industry, currently valued at around $8 billion, has been growing at a robust pace of 10-12 per cent, reflecting strong global outsourcing demand.

- IANS

Share this article:

Reader Comments

A
Arjun K
Reimagining processes is the key. We have brilliant minds in IITs and medical colleges. Strong industry-academia integration, as mentioned, can make India a global hub for AI-driven pharma research. The $8B CRDMO figure is impressive!
R
Rajesh Q
Good to see policymakers and experts on the same page. But the "urgent need to bridge the gap between policy intent and on-ground execution" is the real challenge. We've heard such promises before. Implementation has to be swift this time.
S
Sarah B
As someone working in global health tech, India's scale and talent pool are unmatched for this AI shift. Aligning with European regulatory models is a smart move for global market access. The potential here is enormous.
V
Vikram M
Hope this also means more investment in our government labs and public health data infrastructure. AI needs quality data. We must ensure this tech benefits tier 2/3 cities and villages, not just metro hospitals. Jai Hind!
N
Nikhil C
The focus on venture capital is crucial. Many Indian biotech startups with great ideas fail due to lack of funding in the risky early stages. If the government can de-risk investments, we'll see a flood of innovation. 🤞

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50